Markets
Featured Session: Business, Life, and the Magic of Austin: A Conversation with Michael Dell - Conference - SXSW 2024 Conference and Festivals
Patrick Moorhead and Dell CEO Michael Dell (Photo by Errich Petersen/SXSW Conference & Festivals via Getty Images)

Dell’s stock has risen as much as Nvidia’s, but Dell’s profits haven’t

Dell has been one of the hottest AI stocks of the last year, but is it really benefiting from the AI boom?

Jack Raines
5/16/24 2:02PM

Nvidia has been one of the biggest stock market winners over the last year, with the tech industry’s insatiable demand for AI chips sending its stock up 223%. However, another company has quietly gained 223% this year too: Dell.

Yesterday, Dell shares rose more than 11% after Morgan Stanley raised its price target and predicted the company would benefit from more demand for AI servers.

This comes two months after Nvidia CEO Jensen Huang highlighted the role that Dell is playing in the AI world, saying, “Everybody who is building these chatbots and generative AI, when you’re ready to run it, you’re going to need an AI factory. Nobody is better at building end-to-end systems of very large scale for the enterprise than Dell.”

Surprisingly, Dell’s financial performance hasn’t matched its stock returns. 

Nvidia's ascension to the $2 trillion club coincided with the company growing its revenue and net income by 200% and 800%, since ChatGPT launched in November 2022.

Dell, on the other hand, has lower revenue than it did a year and a half ago, while its earnings have remained flat over the last three years. And Wall Street analysts don't expect operating performance to meaningfully inflect higher in the short term, either: estimates for where both revenues and profits will be in one year's time, if realized, would still leave results below their post-pandemic highs, per Bloomberg.

In Dell's Q4 earnings call, COO Jeffrey Clarke noted that they were seeing increased demand for their AI servers, noting, "AI-optimized server orders increased by nearly 40% sequentially. We shipped $800 million of AI-optimized servers, and our backlog nearly doubled sequentially, exiting the fiscal year at $2.9 billion."

However, that is still a small fraction of Dell's total $22.3 billion in total quarterly revenue, and it did little to slow an 11% drop in year-over-year sales.

Dell may be one of the winners of the AI boom, but so far, the stock has run far ahead of the business.

More Markets

See all Markets
markets

Tesla jumps after Elon Musk discloses buying 2.57 million shares, worth more than $1 billion

Tesla soared in early trading on Monday after CEO Elon Musk disclosed a purchase of 2.57 million shares in the company, according to a new SEC filing.

Per the filing, the "Elon Musk Revocable Trust,” for which the Tesla and SpaceX chief is the trustee, reported acquiring 2.57 million shares, taking its total ownership to 413.36 million shares as of September 12, 2025. The block of equity was bought at prices ranging from $371.38 to $396.54.

Investors are interpreting Musk's latest purchase — his first significant one since February 2020 — as a vote of confidence in the company. Tesla shares are now trading above their Dec. 31 closing price, making the stock positive for the year.

Earlier this month, the board of directors proposed an eye-watering pay package that could award the tech billionaire up to $1 trillion, assuming that very ambitious market cap and fundamental milestones are met.

markets

Hims & Hers falls after FDA commissioner says its Super Bowl ad breached regulations

Hims & Hers is falling in premarket trading after its Super Bowl ad from February was singled out as the “most overt” example of “brazen” marketing tactics among online pharmacies by FDA Commissioner Marty Makary.

The claim, made in an opinion piece written by Makary and published in the JAMA Network on Friday, highlighted the agency’s stricter enforcement policies on pharmaceutical advertisements.

“Equally brazen, online pharmacies are advertising drugs with only upsides mentioned, contributing to America’s culture of overreliance on pharmaceuticals for health,” wrote Makary. “This breach of FDA regulation was most overt earlier this year when Hims & Hers ran a Super Bowl ad highlighting the benefits of glucagon-like peptide-1 drugs without any mention of side effects or disclaimers.”

Hims’ Super Bowl ad touted its direct-to-consumer weight loss medications as “life-changing,” “affordable,” and “doctor-trusted,” billing its approach as “the future of healthcare.”

Google searches for the company spiked after the ad appeared during The Big Game.

Last week, President Donald Trump issued an executive order directing the Secretary of Health and Human Services to crack down on TV drug ads. It was initially unclear whether that order applied to telehealth companies.

Compounded drugs aren’t subject to the same regulatory burdens over their advertisements as branded, FDA-approved drugs made by pharmaceutical companies. For example, Hims can advertise generic Prozac for climax control (an off-label use) while the company that made the drug, Eli Lilly, cannot.

markets

Nvidia falls after Chinese regulator said it violated the country’s antitrust laws in 2020 deal

Nvidia dropped as much as 2.9% in early trading on Monday after China's State Administration for Market Regulation ruled that the chipmaker violated the country's antitrust laws after acquiring Mellanox Technologies, an Israeli-American network solutions supplier.

In 2020, Beijing approved Nvidia's ~$7 billion acquisition under the condition that the chipmaker would not discriminate against Chinese companies. Since then, Nvidia has had to redesign its chips to comply with the US government's regulations that temporarily banned the company from selling its advanced chips, including the H100.

Monday's preliminary finding from the SAMR comes amidst ongoing trade talks between US and Chinese officials in Madrid, with the tariff truce between the world's two largest economies set to expire in November.

As Sherwood’s Luke Kawa noted in August, China has appeared determined to “wean itself off of any dependence on Nvidia and US technology to develop its AI capabilities.”

According to Reuters, under Chinese antitrust law, companies can “face fines of between 1% and 10% of their annual sales from the previous year.” Nvidia’s sales in China generated $17.1 billion of revenue in its most recent fiscal year. Assuming the maximum penalty, the impact would be ~$1.7 billion, less than 1% of Wall Street’s forecast for Nvidia’s total revenue this fiscal year.

markets

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.